pfizer us patient organization funding report 2014

What is the Pfizer Global Health team?

In 2014, Pfizer launched the first executive-level Global Health Team project, deploying 12 senior leaders to volunteer their expertise with a global NGO, Population Services International, with the ultimate goal of assisting this leading international development organization in advancing its public health mission.

What did Pfizer do in Indonesia in 2014?

In 2014, three Pfizer Global Health Fellows served with RTI International in Indonesia to help EMAS enhance its work with civil society groups, improve communication strategies and conduct reviews to better understand the underlying causes of maternal deaths.

How does CTI work at Pfizer?

With four locations in the biomedical research hubs of Boston, New York, San Diego and San Francisco, CTI's open innovation model puts Pfizer scientists in the lab with academic investigators, where they share their understanding of target biology and translational medicine expertise.

What is Pfizer funding?

What is Pfizer's purpose?

Why are global health teams created?

When was Ibrance approved?

How many institutions does CTI have?

Where is Pfizer's lab?

What are the non communicable diseases in Tanzania?

See 2 more topics

About this website

What is Pfizer funding?

Pfizer funds (or co-funds with patient foundations) pre-clinical and clinical development programs and offers equitable intellectual property and ownership rights and access to proprietary technologies. The ultimate goal of each collaborative project is to create a drug candidate that can be moved into further clinical testing.

What is Pfizer's purpose?

At Pfizer, life is our inspiration. And our passion and purpose is to help people live life to the fullest, at every stage of life.

Why are global health teams created?

We have created Global Health Teams to expand and diversify opportunities for colleagues beyond our individual fellowships. Since 2010, more than 60 colleagues have served on cross-functional teams with 19 nonprofit organizations across six countries in Latin America. In 2014, Pfizer launched the first executive-level Global Health Team project, deploying 12 senior leaders to volunteer their expertise with a global NGO, Population Services International, with the ultimate goal of assisting this leading international development organization in advancing its public health mission.

When was Ibrance approved?

Ibrance ® (palbociclib) Approved by the U.S. FDA. On February 3, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Ibrance ® (palbociclib), in combination with letrozole, for the treatment of post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) ...

How many institutions does CTI have?

CTI now has more than 25 academic institutions and five patient group foundations in its network, with a portfolio of projects across a variety of disease areas.

Where is Pfizer's lab?

With four locations in the biomedical research hubs of Boston, New York, San Diego and San Francisco, CTI's open innovation model puts Pfizer scientists in the lab with academic investigators, where they share their understanding of target biology and translational medicine expertise.

What are the non communicable diseases in Tanzania?

NCDs include a range of chronic conditions, including cancer, diabetes, cardiovascular disease and hypertension, as well as Alzheimer's and other dementias. They are commonly thought of as “ diseases of affluence, ” whereas, in reality, four-fifths of deaths from NCDs are in low- and middle-income countries and older people in developing countries are particularly at risk. Prevention through an active and healthy lifestyle can turn some of these debilitating diseases into manageable conditions.

What is Pfizer funding?

Pfizer funds (or co-funds with patient foundations) pre-clinical and clinical development programs and offers equitable intellectual property and ownership rights and access to proprietary technologies. The ultimate goal of each collaborative project is to create a drug candidate that can be moved into further clinical testing.

What is Pfizer's purpose?

At Pfizer, life is our inspiration. And our passion and purpose is to help people live life to the fullest, at every stage of life.

Why are global health teams created?

We have created Global Health Teams to expand and diversify opportunities for colleagues beyond our individual fellowships. Since 2010, more than 60 colleagues have served on cross-functional teams with 19 nonprofit organizations across six countries in Latin America. In 2014, Pfizer launched the first executive-level Global Health Team project, deploying 12 senior leaders to volunteer their expertise with a global NGO, Population Services International, with the ultimate goal of assisting this leading international development organization in advancing its public health mission.

When was Ibrance approved?

Ibrance ® (palbociclib) Approved by the U.S. FDA. On February 3, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Ibrance ® (palbociclib), in combination with letrozole, for the treatment of post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) ...

How many institutions does CTI have?

CTI now has more than 25 academic institutions and five patient group foundations in its network, with a portfolio of projects across a variety of disease areas.

Where is Pfizer's lab?

With four locations in the biomedical research hubs of Boston, New York, San Diego and San Francisco, CTI's open innovation model puts Pfizer scientists in the lab with academic investigators, where they share their understanding of target biology and translational medicine expertise.

What are the non communicable diseases in Tanzania?

NCDs include a range of chronic conditions, including cancer, diabetes, cardiovascular disease and hypertension, as well as Alzheimer's and other dementias. They are commonly thought of as “ diseases of affluence, ” whereas, in reality, four-fifths of deaths from NCDs are in low- and middle-income countries and older people in developing countries are particularly at risk. Prevention through an active and healthy lifestyle can turn some of these debilitating diseases into manageable conditions.